Biomarker clinical phase outsourcing market seen reaching $30.4 billion by 2030
The biomarker clinical phase outsourcing services market is projected to grow from $11.91 billion in 2025 to $30.4 billion by 2030, according to a new industry report. The surge reflects rising clinical trial complexity, more oncology and precision medicine research, and heavier use of biomarker analytics.
Why it matters: - Biomarker outsourcing is becoming a bigger part of clinical development as trials get more specialized and data-heavy. - The market’s projected climb to $30.4 billion by 2030 signals rising demand for services tied to personalized medicine, precision oncology and biomarker validation. - The shift could shape how drug makers design trials, manage data and meet regulatory expectations.
What happened: - The Business Research Company said the biomarker clinical phase outsourcing services market will rise from $11.91 billion in 2025 to $14.62 billion in 2026. - The company projected the market will reach $30.4 billion by 2030. - The report put 2026 growth at a 22.7% compound annual growth rate and 2030 growth at 20.1%. - The report is titled The Biomarker Clinical Phase Outsourcing Services Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The company also offered a free sample of the report.
The details: - Biomarker clinical phase outsourcing services involve contracting specialized companies or institutions to handle biomarker-related tasks during clinical trials. - Biomarkers are measurable biological indicators used to monitor treatment safety or effectiveness in medical research and testing. - Growth has been fueled by more complex trial designs, stronger oncology research activity, biomarker-focused drug development, translational research initiatives and more collaboration with specialist providers. - Looking ahead, demand is expected to rise on the back of personalized medicine trials, AI-powered biomarker analytics, multi-biomarker studies, investment in precision oncology and stricter biomarker validation requirements. - The report flagged more outsourcing of biomarker-related trial functions, wider use of predictive and prognostic biomarkers, greater use of omics-based analysis, companion diagnostics development and a stronger focus on precision medicine trials. - The report said North America held the largest market share in 2025. - The report also covered Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company said the report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables.
Between the lines: - The growth forecast reflects how biomarker work is moving from a niche support function to a core part of trial execution. - The report linked market expansion to the broader rise in clinical trial volume worldwide. - As of November 2025, ClinicalTrials.gov listed 558,242 studies across all 51 U.S. states and 224 countries and territories worldwide, according to the National Library of Medicine. - That trial count underscores why sponsors may need more outside expertise for biomarker discovery, validation and data analysis.
What's next: - The market is expected to keep expanding through 2030 as drug developers lean more heavily on biomarker-driven trial design. - Service providers may see more demand for AI-enabled analytics, multi-biomarker workflows and companion diagnostics support. - The report suggests regional competition will continue across North America, Europe and Asia, with North America currently leading.
The bottom line: - Biomarker clinical phase outsourcing is moving into a high-growth phase as clinical trials become more personalized, more complex and more dependent on specialized data services. - View the full report
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Coast To Coast Tribune
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.